1) Arakawa R, Okumura M, Ito H, et al:Positron emission tomography measurement of dopamine D2receptor occupancy in the pituitary and cerebral cortex:Relation to antipsychotic-induced hyperprolactinemia. J Clin Psychiatry 71:1131-1137, 2010
2) Broekhof R, Gosselink MJ, Pijl H, et al:The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis. Gen Hosp Psychiatry 34:209. e1-3, 2012
3) Li X, Tang Y, Wang C:Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia:Meta-analysis of randomized controlled trials. PLoS One 8:e70179, 2013
4) Liao WT, Bai YM:Major depressive disorder induced by prolactinoma:A case report. Gen Hosp Psychiatry 36:125. e1-2, 2014
5) 長嶺敬彦:受容体から神経回路へのパラダイム・シフト.臨床精神薬理14:289-292, 2011
6) Nakamura M, Nagamine T:Hypoprolactinemia and extrapyramidal symptoms treated with aripiprazole in male schizophrenia or psychotic affective disorder subjects. Clin Neuropsychopharmacol Ther 3:18-22, 2012
7) Ozaki N, Otsubo T, Kato M, et al:Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder:A subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter Efficacy study. Psychiatry Clin Neurosci 69:34-42, 2015
8) Ali S, Miller KK, Freudenreich O:Management of Psychosis Associated With a Prolactinoma:Case Report and Review of the Literature. Psychosomatics 51:370-376, 2010
9) Weitzner MA, Kanfer S, Booth-Jones M:Apathy and pituitary disease:It has nothing to do with depression. J Neuropsychiatry Clin Neurosci 17:159-166, 2005